💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Zileuton

CHEMBL93 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
236.3 g/mol
LogP
1.6
Phase
4

Zileuton is a 5-lipoxygenase (5-LOX) inhibitor that blocks the enzyme responsible for converting arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and subsequently to leukotrienes, potent inflammatory mediators that cause bronchoconstriction, mucus secretion, and inflammatory cell recruitment in asthma. It is approved for the prophylaxis and chronic treatment of asthma, reducing leukotriene-mediated airway inflammation and bronchoconstriction. Its direct enzyme inhibition of leukotriene synthesis distinguishes it from leukotriene receptor antagonists like montelukast.

น้ำหนักโมเลกุล

236.2900 g/mol

LogP

1.60

TPSA

94.80 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Non-Small Cell Lung Cancer Asthma Leukemia

กลไกการออกฤทธิ์

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(c1cc2ccccc2s1)N(O)C(N)=O

                

                

                
                

                    
InChI

                    
InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)

                

                

                

                    
                    

                        
Molecular Formula

                        
C11H12N2O2S

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
พันธะที่หมุนได้

                        
2

                    

                    
                    
                    

                        
อะตอมหนัก

                        
16

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
Zileuton is a 5-lipoxygenase (5-LOX) inhibitor that blocks the enzyme responsible for converting arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and subsequently to leukotrienes, potent inflammatory mediators that cause bronchoconstriction, mucus secretion, and inflammatory cell recruitment in asthma. It is approved for the prophylaxis and chronic treatment of asthma, reducing leukotriene-mediated airway inflammation and bronchoconstriction. Its direct enzyme inhibition of leukotriene synthesis distinguishes it from leukotriene receptor antagonists like montelukast.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Zileuton is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL93.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 60490.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.